A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB928, a Novel Dual Adenosine Receptor Antagonist, in Combination with Chemotherapy in Patients with Breast or Gynecologic Malignancies

De Souza P1, Lee CK2, Sjoquist K2, Pan S3, Idan A3, Rieger A4, Berry W4, Jin L4, Seitz L4, Ashok D4, Walters MJ4, Piovesan D4, Tan JBL4, Lee SJ4, Park A4, DiRienzo D4, Karakunnel J4

1University of Western Sydney, Sydney, Australia; 2Cancer Care Centre, St. George Public Hospital, Kogarah, NSW 2217, Australia; 3St. George Private Hospital, Kogarah, NSW 2217, Australia; 4Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, CA 94545, USA

Abstract No. 1068

ABSTRACT

Background: In many tumors, extracellular adenosine contributes to an immunosuppressed tumor microenvironment via activation of the A3 receptor (A3R) and A2a receptor (A2aR) expressed on intratumoral immune cells. AB928 is a novel, selective, small-molecule antagonist of both A3R and A2aR with the ability to potently block the immunosuppressive effects of high concentrations of adenosine in the tumor microenvironment. AB928 differs from other known A2aR antagonists based on its dual mode of action, its minimal loss of potency due to nonspecific binding to plasma proteins, and its lack of penetration through a healthy blood-brain barrier. Preclinically, combining adenosine receptor inhibition with either chemotherapy or anti-programmed cell death-1 (PD-1) resulted in greater tumor control in mouse models, suggesting that AB928 may have synergistic activity when paired with either chemotherapy or checkpoint inhibitors in oncology patients. A phase 1 study with AB928 in healthy volunteers has been completed.

Methods: A phase 1/1b, open-label, dose-escalation (3+3 design) study is evaluating the safety/tolerability (including dose-limiting toxicities [DLTs]), pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of AB928 in combination with pegylated liposomal doxorubicin (PLD) in patients with breast or gynecologic malignancies. Patients are eligible if they have pathologically confirmed triple-negative breast cancer (TNBC) or ovarian cancer (OC) that is metastatic, advanced or recurrent with progression for which no alternative or curative therapy exists. Patients may have received up to 5 lines of prior therapies for advanced/recurrent and progressive disease (unlimited number of hormonal therapies permitted). AB928 is administered orally once daily at a starting dose of 75 mg (Cohort 1) escalating to 150 mg (Cohort 2) and 200 mg (Cohort 3), and PLD is administered at the standard regimen of 40 mg/m² intravenously (IV) every 4 weeks (Q4W). Intermediate AB928 doses may be evaluated based on data from cohorts that have been explored. Doses that have exceeded the maximum tolerated dose (MTD) will not be evaluated. Following the identification of the recommended phase 2 dose (RP2D) of AB928 and PLD during dose escalation, each tumor cohort (TNBC and OC) may be expanded to further evaluate the combination. The primary endpoint is safety/tolerability, and secondary endpoints are PK, PD (receptor occupancy in peripheral blood and immunomodulatory activity in select immune subsets), and clinical activity (objective response rate [ORR], duration of response, disease control rate [DCR], complete response [CR], partial response [PR], or stable disease [SD] for >6 months), and progression-free survival [PFS] per Response Evaluation Criteria in Solid Tumors [RECIST] v1.1, and overall survival. The study is recruiting.

BACKGROUND

- The accumulation of adenosine, generated through hydrolysis of extracellular adenosine monophosphate (AMP) by the ectonucleotidase CD73, is a key strategy exploited by tumors to escape immunosurveillance (Figure 1).2
- Adenosine’s suppressive effects on immune cells are driven primarily by 2 of the 4 adenosine receptors, A3R and A2aR.1
- This effect is mediated by increased cyclic AMP (cAMP) levels and phosphorylation of cAMP response element binding protein (CREB) by PKA.
- Pharmacological inhibition of the effects of adenosine has recently generated much interest in immunology, but thus far, only A2aR antagonists, initially developed for central nervous system indications,4 are being studied in oncology.

METHODS

- Dose escalation: Pathologically confirmed TNBC or OC that is metastatic, advanced or recurrent with progression for which no alternative/curative therapy exists
- Any number of prior therapies for advanced/recurrent and progressive disease
- Dose expansion: Pathologically confirmed TNBC that is metastatic, recurrent with progression for which no alternative/curative therapy exists or physician and patient consider this option appropriate, or platinum-resistant OC (ie, having received a platinum agent in first-line setting)
- ≥1 measurable lesion per RECIST v1.1
- Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1

Key Exclusion Criteria

- Live vaccines within 4 weeks of study drug initiation
- Pregnant or breastfeeding
- Active or prior autoimmune disease requiring systemic treatment
- Prior chemoradiotherapy, targeted small-molecule therapy, or radiotherapy within 4 weeks of study drug initiation or has not recovered from AEs resulting from previous agents

Endpoints

Primary Endpoint

- Safety: Incidence of AEs and DLTs, and changes from baseline in vital signs, clinical laboratory parameters, physical examination findings, ECOG performance status, and electrocardiogram

Secondary Endpoints

- Serum concentration and PK parameters for AB928
- Receptor occupancy in peripheral blood and immunomodulatory activity in select immune subsets for AB928
- Clinical activity: ORR, duration of response, DCR (defined as CR, PR, or SD for >6 months), and PFS per RECIST v1.1, and overall survival

Statistical Analysis

- Summary statistics will be provided for AEs, serious AEs, AE severity, and relationship to study drug
- PK parameters will be estimated using noncompartmental methods
- DLT and DCR will be estimated by the proportion of patients with objective response and disease control, respectively, and their 95% confidence intervals will be estimated using the exact binomial method
- Time-to-event endpoints will be summarized using the Kaplan-Meier method
- Interim analyses for futility and toxicity will be conducted for each expansion cohort

Trial Status

- Enrollment is ongoing

REFERENCES